As angiogenesis was recognized as a core hallmark of cancer growth and survival, several
strategies have been implemented to target the tumour vasculature. Yet to date, attempts …

Ovarian cancer is one of the leading causes of death in patients with gynecological
malignancy. Despite optimal cytoreductive surgery and platinum-based chemotherapy …

We conducted a pilot clinical trial testing a personalized vaccine generated by autologous
dendritic cells (DCs) pulsed with oxidized autologous whole-tumor cell lysate (OCDC) …

Purpose In platinum-resistant ovarian cancer (OC), single-agent chemotherapy is standard.
Bevacizumab is active alone and in combination. AURELIA is the first randomized phase III …

Background Angiogenesis plays a role in the biology of ovarian cancer. We examined the
effect of bevacizumab, the vascular endothelial growth factor inhibitor, on survival in women …

The biology of ovarian carcinoma differs from that of hematogenously metastasizing tumors
because ovarian cancer cells primarily disseminate within the peritoneal cavity and are only …

Importance Treatment options for recurrent ovarian cancer are of limited clinical benefit and
adversely affect patient quality of life, representing an unmet need for tolerable effective …

Purpose This randomized, multicenter, blinded, placebo-controlled phase III trial tested the
efficacy and safety of bevacizumab (BV) with gemcitabine and carboplatin (GC) compared …

Epithelial ovarian cancer is the most lethal of the gynecologic malignancies, largely due to
the advanced stage at diagnosis in most patients. Screening strategies using ultrasound and …

Objective Ovarian cancer is the deadliest gynecologic malignancy and the fifth leading
cause of death from cancer in women in the US Since overall survival remains poor, there is …